It has been indicated that the addition of chemotherapy is enough for the treatment of patients with AML with NPM1 mutations in the absence of FLT3-ITD mutations, and it is unnecessary to perform autologous or allogenic stem cell transplantation. The gene discussed is NPM1; the disease is acute myeloid leukemia.